



Biocitech life science park welcomes Pherecydes Pharma

**The arrival of Pherecydes Pharma boosts Biocitech's reputation as
a centre for anti-infectious research and brings the total of
residents to 22**

Paris, October 6, 2008--Biocitech, the Paris life science technology park, today announces that Pherecydes Pharma is the latest company to join the 21 other resident companies on its campus. This means the park's occupancy rate is now 93 percent.

Pherecydes Pharma S.A. is a biosecurity and biodefense company. It is developing innovative biopharmaceutical solutions to threats from bacteria as well as therapeutic and identification tools based on phage technology. The company offers biosensors for the real time identification of bacteria and solutions for surface decontamination. The company (CEO Thierry Raynaud) is a spin-off from the research activities of Bio-Modeling Systems SAS, a predictive integrative biology specialist.

"Anti-infectious research has always been part of the culture and history of the Biocitech site," said Biocitech CEO, Jacques Lhomel. "We are really pleased to welcome Pherecydes Pharma as its activities are complementary to and will strengthen the anti-infectious research network already present at Biocitech. Its arrival will be a source of new inter-company synergies, one of the key concepts driving the development of the park."

"We chose Biocitech for three reasons: its nearness to Paris, the quality of the accommodation and the services it offers," said Manuel Géa, co-founder of Pherecydes Pharma and CEO of Bio-Modeling Systems. "It is a technology park with very comprehensive facilities and is especially suited to start-ups. Biocitech was the only technology park we found able to support the rapid development of Pherecydes Pharma. And we knew that the site had a ready-made network of anti-infectious focused companies which will allow us to develop strategic collaborations."

Biocitech will be present at the EuroBio2008 congress from October 7-9, 2008, at the Palais des Congrès in Paris where it will share a large stand (I2-I9) with the Seine-Saint-Denis Committee for Expansion and the Seine-Saint-Denis General Council as well as three other Biocitech residents Discngine, Mutabilis and Oroxcell.

For more information on Pherecydes Pharma: www.pherecydes-pharma.com

About Biocitech

The Biocitech technology park for life sciences offers a world-class environment and services for the development of biotechnology, biopharmaceutical and fine chemical companies.

Biocitech is on the outskirts of Paris, only 20 minutes from the city center and Charles de Gaulle airport. It is privately-owned and provides secure premises and comprehensive facilities based on the latest technology. It has received regulatory approval for conformity to environmental protection standards. Companies can use one or many of the services offered. These include offices, laboratories and a range of technical and scientific services - all designed to let entrepreneurs concentrate their time and resources on their core business.

Companies already established at Biocitech represent a wide variety of complementary disciplines and many are working on collaborative projects.

Along with other organizations in the Ile-de-France region around Paris, Biocitech plays a key role in the Medicen Paris Region network. This is a healthcare and new therapy cluster designated by the French government as internationally competitive and hence qualified for special privileges.

For further information: <http://www.biocitech.com>

Contact Press and Analysts
Andrew Lloyd & Associates
Andrew Lloyd – Cécilia Derrien
Tel : +33 1 56 54 07 00
allo@ala.com - cecilia@ala.com
